Haemodynamic response to dopexamine hydrochloride in postinfarction heart failure: lack of tolerance after continuous infusion
- PMID: 3224052
- PMCID: PMC1224889
- DOI: 10.1136/hrt.60.6.489
Haemodynamic response to dopexamine hydrochloride in postinfarction heart failure: lack of tolerance after continuous infusion
Abstract
Dopexamine is a new vasodilator with a combination of dopamine receptor and beta 2 adrenoreceptor agonist properties. Its haemodynamic effects were assessed after dose titration and during infusion for up to 24 hours in 15 patients with heart failure after acute myocardial infarction. At the initial titration a dose of 1 micrograms/kg/min produced a 25% decrease in the systemic vascular resistance index and a 32% increase in cardiac index. Stroke volume index and heart rate increased by 23% and 9% respectively. Left ventricular filling pressures and mean blood pressures were not affected. The short term effects were well sustained during the long term infusion and tolerance did not develop. Administration of dopexamine to patients with heart failure after acute myocardial infarction augments cardiac performance at rest.
Similar articles
-
Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure.Eur Heart J. 1986 Aug;7(8):697-703. doi: 10.1093/oxfordjournals.eurheartj.a062125. Eur Heart J. 1986. PMID: 2876894
-
[Dopexamine: a new dopaminergic agonist].Ann Fr Anesth Reanim. 1993;12(3):308-20. doi: 10.1016/s0750-7658(05)80658-6. Ann Fr Anesth Reanim. 1993. PMID: 7902685 Review. French.
-
Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure.Int J Cardiol. 1991 Feb;30(2):203-8. doi: 10.1016/0167-5273(91)90096-8. Int J Cardiol. 1991. PMID: 2010243 Clinical Trial.
-
Hemodynamic effects of dopexamine hydrochloride infusions of 48 to 72 hours' duration for severe congestive heart failure.Am J Cardiol. 1988 Aug 11;62(5):83C-88C. doi: 10.1016/s0002-9149(88)80074-2. Am J Cardiol. 1988. PMID: 3407599
-
Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?Basic Res Cardiol. 1989;84 Suppl 1:177-86. doi: 10.1007/BF02650357. Basic Res Cardiol. 1989. PMID: 2573340 Review.
Cited by
-
The effects of dopexamine, a new dopamine analogue, on platelet function in stress.Br J Clin Pharmacol. 1990 Jul;30(1):87-95. doi: 10.1111/j.1365-2125.1990.tb03747.x. Br J Clin Pharmacol. 1990. PMID: 2390435 Free PMC article.
-
Chronic opioid therapy and opioid tolerance: a new hypothesis.Pain Res Treat. 2013;2013:407504. doi: 10.1155/2013/407504. Epub 2013 Jan 14. Pain Res Treat. 2013. PMID: 23401765 Free PMC article.
-
Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.Drugs. 1990 Feb;39(2):308-30. doi: 10.2165/00003495-199039020-00009. Drugs. 1990. PMID: 1970288 Review.
-
Circulatory and diuretic effects of dopexamine infusion in low-birth-weight infants with respiratory failure.Intensive Care Med. 1996 Jan;22(1):65-70. doi: 10.1007/BF01728334. Intensive Care Med. 1996. PMID: 8857441 Clinical Trial.
-
Biochemical, autoradiographic and pharmacological evidence for the involvement of tubular DA-1 receptors in the natriuretic response to dopexamine hydrochloride.Naunyn Schmiedebergs Arch Pharmacol. 1991 Jan;343(1):21-30. doi: 10.1007/BF00180672. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1674360
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical